Phase II Study of Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer Resistant to Endocrine Therapy

Trial Profile

Phase II Study of Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer Resistant to Endocrine Therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Vinorelbine (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms VinoMetro
  • Most Recent Events

    • 08 Sep 2017 Trial design presented at 42nd European Society for Medical Oncology Congress.
    • 08 Sep 2017 According to trial design presented at 42nd European Society for Medical Oncology Congress, 5 patients were enrolled till 30 Apr 2017 and it is planned to include 45 (39 evaluable) patients at 8 German sites until September 2018.
    • 08 Feb 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top